Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upper Extremity Injection of Xeomin® and Changes in Gait Related Mobility in Adults After Stroke
NCT04908423Phase 4Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Oct 2021
- Primary completion
- Apr 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of botulinum toxin type A in stroke, sponsored by Wake Forest University Health Sciences. Started Oct 2021; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
stroke
Beyond the preview
Go deeper on NCT04908423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908423.